Compass Therapeutics, Inc. Share Price
Stocks
CMPX
US20454B1044
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
01:30:00 22/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 0.8145 USD | -2.26% |
|
-7.34% | -84.83% |
| 23/09 | Compass Therapeutics Shares Drop After Downgrade From Wedbush | MT |
| 23/09 | Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5 | MT |
| Market Cap | 15Cr 13Cr 12Cr 11Cr 21Cr 1.38TCr 21Cr 145.09Cr 57Cr 727.58Cr 55Cr 54Cr 2.32TCr | P/E 2026 * |
-1.64x | P/E 2027 * | -1.46x |
|---|---|---|---|---|---|
| Enterprise Value | -33.18L -29.57L -27.38L -24.78L -46.68L -31Cr -47.23L -3.28Cr -1.29Cr -16Cr -1.24Cr -1.22Cr -52Cr | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 2.1x |
| Free-Float |
87.53% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| CMPX | Delayed | |
CBOE
| CMPX | Real-time |
Last Transcript: Compass Therapeutics, Inc.
| 1 day | -2.26% | ||
| 1 week | -7.34% | ||
| Current month | -21.68% | ||
| 1 month | -55.25% | ||
| 3 months | -61.21% | ||
| 6 months | -84.46% | ||
| Current year | -84.83% |
| 1 week | 0.81 |  | 0.91 |
| 1 month | 0.81 | | 1.23 |
| Current year | 0.81 | | 6.88 |
| 1 year | 0.81 | | 6.88 |
| 3 years | 0.76 | | 6.88 |
| 5 years | 0.76 | | 6.88 |
| 10 years | 0.76 | | 11 |
| Manager | Title | Age | Since |
|---|---|---|---|
Thomas Schuetz
CEO | Chief Executive Officer | 65 | 28/05/2024 |
Barry Shin
DFI | Director of Finance/CFO | 54 | 09/12/2024 |
Bing Gong
CTO | Chief Tech/Sci/R&D Officer | 50 | 01/01/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Schuetz
BRD | Director/Board Member | 65 | 01/01/2014 |
Phil Ferneau
BRD | Director/Board Member | 64 | 01/01/2015 |
Carl Gordon
CHM | Chairman | 61 | 01/01/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/10/26 | Buy | Controller/Auditor | 20,000 | 0.0111% | ||
| 24/09/26 | Buy | Controller/Auditor | 2,500 | 0.0014% | ||
| 29/04/26 | Buy | Controller/Auditor | 15,000 | 0.0083% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.26% | -7.34% | -80.13% | -58.86% | 15Cr | |
| -0.21% | -4.43% | +44.40% | +74.13% | 6.62TCr | |
| -2.64% | +1.13% | +8.18% | +70.15% | 5.52TCr | |
| +0.35% | +3.74% | +11.86% | +91.21% | 5.28TCr | |
| +3.28% | +5.58% | +26.51% | +50.05% | 4.55TCr | |
| +0.51% | +9.95% | +22.40% | +133.92% | 4.39TCr | |
| -1.15% | +0.39% | +263.21% | +594.60% | 4.16TCr | |
| +0.10% | +9.90% | +16.11% | +59.33% | 3.4TCr | |
| -8.38% | -6.95% | +26.35% | -1.93% | 2.58TCr | |
| +0.53% | +4.19% | +37.24% | +27.11% | 2.35TCr | |
| Average | -0.97% | +2.93% | +37.61% | +103.97% | 3.89TCr | |
| Weighted average by Cap. | -0.54% | +3.72% | +49.54% | +126.32% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 65.12L 58.03L 53.72L 48.62L 91.6L 61Cr 92.68L 6.44Cr 2.53Cr 32Cr 2.44Cr 2.39Cr 102.93Cr |
| Net income | -9.33Cr -8.31Cr -7.69Cr -6.96Cr -13Cr -880.11Cr -13Cr -92Cr -36Cr -462.62Cr -35Cr -34Cr -1.47TCr | -11Cr -9.95Cr -9.22Cr -8.34Cr -16Cr -1.05TCr -16Cr -110.5Cr -43Cr -554.12Cr -42Cr -41Cr -1.77TCr |
| Net Debt | -15Cr -13Cr -12Cr -11Cr -21Cr -1.42TCr -21Cr -148.38Cr -58Cr -744.04Cr -56Cr -55Cr -2.37TCr | -13Cr -12Cr -11Cr -9.93Cr -19Cr -1.26TCr -19Cr -131.56Cr -52Cr -659.71Cr -50Cr -49Cr -2.1TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/26/21 | $0.8145 | -2.26% | 15,44,138 |
| 20/26/20 | $0.8333 | -0.20% | 18,83,132 |
| 19/26/19 | $0.8350 | -2.91% | 31,19,040 |
| 16/26/16 | $0.8600 | -4.09% | 20,38,934 |
| 15/26/15 | $0.8967 | +2.01% | 33,39,175 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CMPX Stock
Select your edition
All financial news and data tailored to specific country editions
